

To:

Head of Paediatric Medicines
European Medicines Agency
30 Churchill Place
London E14 5EU
United Kingdom
paediatrics@ema.europa.eu

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): Recombinant human monoclonal antibody to human interleukin (IL)-17A

Invented name: Secukinumab

Latest Decision number(s): 1) P/237/2010 2) P/ 3) P/ 4) P/

Corresponding PIP number(s): 1) EMEA-000380-PIP04-10 2) EMEA- 3) EMEA- 4) EMEA-

Please note that development of the medicinal product above in the [condition(s)/indication(s)]:
chronic non-infectious uveitis

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☒ other reason (please specify: internal decision on development portfolio)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

Following an internal decision on the Novartis' development portfolio, the recombinant human monoclonal antibody to human interleukin (IL)-17A in the treatment of non-infectious uveitis (AIN457C) has been discontinued.

Name and signature of the PIP contact point: Signature on file

Date: 05 May 2015

Contact for inquiries from interested parties: Novartis Paediatric Enquiries

Telephone:

Email:

paediatric.enquiries@novartis.com